Caladrius Biosciences

Cardiovascular disease

In 2012 they started a phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow derived cell therapy enriched for CD34+ cells, for Acute Myocardial Infarction. Initial results included a statistically significant mortality benefit. After the interim results reported in Nov 2014 the company clarified the changes to the study.

Cancer therapies

The cancer therapies (Melapuldencel-T and ovapuldencel-T) below are an autologous dendritic cell-based immunotherapy using the patients own dendritic cells and samples of their tumour to make dendritic cells aimed at the patients tumour antigens. This should activate T cells to attack the tumour.

Pipeline - Therapies in development

CLBS03

a T regulatory cell therapy candidate for type 1 diabetes - in Phase II.

CLBS20 (Melapuldencel-T)

(Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells In GM-CSF) for metastatic melanoma - (based on a new antigen presentation and T cell activation approach) Phase III clinical trials abandoned Jan 2016 (due to competitive therapies).

ovapuldencel-T

(autologous dendritic cells loaded with irradiated autologous tumor cells in GM-CSF) for ovarian cancer. Phase 2 trial registered. As of January 2016 Not active.

CLBS12

(autologous CD34+ cells) for critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO). As of January 2016 this phase 2 trial has not started. (CD34+ cells include many types of hematopoietic stem cell.)